Page last updated: 2024-09-05

sb 216763 and Deafness, Transitory

sb 216763 has been researched along with Deafness, Transitory in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bae, GS; Chong, MS; Hwang, SY; Jung, WS; Kim, DY; Kim, EK; Kim, HJ; Kim, MS; Kwon, KB; Park, CS; Park, HJ; Park, RK; Park, SJ; Seo, SW; Song, HJ; Song, MY1

Other Studies

1 other study(ies) available for sb 216763 and Deafness, Transitory

ArticleYear
Selective GSK-3beta inhibitors attenuate the cisplatin-induced cytotoxicity of auditory cells.
    Hearing research, 2009, Volume: 257, Issue:1-2

    Topics: Acoustic Stimulation; Animals; Antineoplastic Agents; Apoptosis; Caspases; Cell Line; Cisplatin; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme Activation; Evoked Potentials, Auditory, Brain Stem; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Hair Cells, Auditory; Hearing Loss; Indoles; Injections, Intraperitoneal; Interleukin-1beta; Interleukin-6; Lithium Chloride; Maleimides; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Organ Culture Techniques; Organ of Corti; Phosphorylation; Protein Kinase Inhibitors; Rats; Rats, Sprague-Dawley; Time Factors; Tumor Necrosis Factor-alpha

2009